These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 34187084)

  • 1. NKG2D defines tumor-reacting effector CD8
    Mojic M; Shitaoka K; Ohshima C; Ucche S; Lyu F; Hamana H; Tahara H; Kishi H; Hayakawa Y
    Cancer Sci; 2021 Sep; 112(9):3484-3490. PubMed ID: 34187084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topical treatment of all-trans retinoic acid inhibits murine melanoma partly by promoting CD8
    Yin W; Song Y; Liu Q; Wu Y; He R
    Immunology; 2017 Oct; 152(2):287-297. PubMed ID: 28556970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impaired tumor rejection by memory CD8 T cells in mice with NKG2D dysfunction.
    André MC; Sigurdardottir D; Kuttruff S; Pömmerl B; Handgretinger R; Rammensee HG; Steinle A
    Int J Cancer; 2012 Oct; 131(7):1601-10. PubMed ID: 21607945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
    Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
    Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth.
    Hervieu A; Rébé C; Végran F; Chalmin F; Bruchard M; Vabres P; Apetoh L; Ghiringhelli F; Mignot G
    J Invest Dermatol; 2013 Feb; 133(2):499-508. PubMed ID: 22951720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of SHP-1 Expands the Repertoire of Antitumor T Cells Available to Respond to Immune Checkpoint Blockade.
    Snook JP; Soedel AJ; Ekiz HA; O'Connell RM; Williams MA
    Cancer Immunol Res; 2020 Apr; 8(4):506-517. PubMed ID: 32075800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. STING Agonist Combined to a Protein-Based Cancer Vaccine Potentiates Peripheral and Intra-Tumoral T Cell Immunity.
    Rossi M; Carboni S; Di Berardino-Besson W; Riva E; Santiago-Raber ML; Belnoue E; Derouazi M
    Front Immunol; 2021; 12():695056. PubMed ID: 34276686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An agonistic anti-Toll-like receptor 4 monoclonal antibody as an effective adjuvant for cancer immunotherapy.
    Tsukamoto H; Kubota K; Shichiku A; Maekawa M; Mano N; Yagita H; Ohta S; Tomioka Y
    Immunology; 2019 Oct; 158(2):136-149. PubMed ID: 31515801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiofrequency radiation reshapes tumor immune microenvironment into antitumor phenotype in pulmonary metastatic melanoma by inducing active transformation of tumor-infiltrating CD8
    Jiao JZ; Zhang Y; Zhang WJ; He MD; Meng M; Liu T; Ma QL; Xu Y; Gao P; Chen CH; Zhang L; Pi HF; Deng P; Wu YZ; Zhou Z; Yu ZP; Deng YC; Lu YH
    Acta Pharmacol Sin; 2024 Jul; 45(7):1492-1505. PubMed ID: 38538718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The helminth-derived peptide GK-1 induces an anti-tumoral CD8 T cell response associated with downregulation of the PD-1/PD-L1 pathway.
    Rodríguez-Rodríguez N; Madera-Salcedo IK; Bugarin-Estrada E; Sánchez-Miranda E; Torres-García D; Cervantes-Torres J; Fragoso G; Rosetti F; Crispín JC; Sciutto E
    Clin Immunol; 2020 Mar; 212():108240. PubMed ID: 31299381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NKG2D signaling certifies effector CD8 T cells for memory formation.
    Perez C; Prajapati K; Burke B; Plaza-Rojas L; Zeleznik-Le NJ; Guevara-Patino JA
    J Immunother Cancer; 2019 Feb; 7(1):48. PubMed ID: 30777125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Type I-polarized BRAF-pulsed dendritic cells induce antigen-specific CD8+ T cells that impact BRAF-mutant murine melanoma.
    Cintolo JA; Datta J; Xu S; Gupta M; Somasundaram R; Czerniecki BJ
    Melanoma Res; 2016 Feb; 26(1):1-11. PubMed ID: 26451873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induced pluripotent stem cell-derived myeloid cells expressing OX40 ligand amplify antigen-specific T cells in advanced melanoma.
    Kimura T; Fukushima S; Okada E; Kuriyama H; Kanemaru H; Kadohisa-Tsuruta M; Kubo Y; Nakahara S; Tokuzumi A; Kajihara I; Makino K; Miyashita A; Aoi J; Makino T; Tsukamoto H; Nishimura Y; Inozume T; Zhang R; Uemura Y; Senju S; Ihn H
    Pigment Cell Melanoma Res; 2020 Sep; 33(5):744-755. PubMed ID: 32353897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses.
    Dobrzanski MJ; Reome JB; Hollenbaugh JA; Dutton RW
    J Immunol; 2004 Feb; 172(3):1380-90. PubMed ID: 14734713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploiting in situ antigen generation and immune modulation to enhance chemotherapy response in advanced melanoma: A combination nanomedicine approach.
    Lu Y; Wang Y; Miao L; Haynes M; Xiang G; Huang L
    Cancer Lett; 2016 Aug; 379(1):32-8. PubMed ID: 27235608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells.
    Gao X; Wang X; Yang Q; Zhao X; Wen W; Li G; Lu J; Qin W; Qi Y; Xie F; Jiang J; Wu C; Zhang X; Chen X; Turnquist H; Zhu Y; Lu B
    J Immunol; 2015 Jan; 194(1):438-45. PubMed ID: 25429071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of melanoma growth after treatment with dendritic cells in a Tyr-SV40E murine model requires CD4+ T cells but not CD8+ T cells.
    Milling SW; Sai T; Silvers WK; Mintz B
    Melanoma Res; 2004 Dec; 14(6):555-62. PubMed ID: 15577330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD8+T cell-specific induction of NKG2D receptor by doxorubicin plus interleukin-12 and its contribution to CD8+T cell accumulation in tumors.
    Hu J; Zhu S; Xia X; Zhang L; Kleinerman ES; Li S
    Mol Cancer; 2014 Feb; 13():34. PubMed ID: 24565056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD8
    Xu C; Lu X; Liu W; Chen A; Meng G; Zhang H; Li B; Zhang Y; Wu J; Wei J
    J Transl Med; 2018 May; 16(1):132. PubMed ID: 29784005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD8(+) T cell response to adenovirus vaccination and subsequent suppression of tumor growth: modeling, simulation and analysis.
    Wang Q; Klinke DJ; Wang Z
    BMC Syst Biol; 2015 Jun; 9():27. PubMed ID: 26048402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.